- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00607880
Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy
A Prospective Randomized Study of the Vortex® Implantable Access Port Versus the BardPort™ Implantable Port in Cancer Patients Receiving Adjuvant Intravenous Chemotherapy
RATIONALE: Giving chemotherapy drugs through an implanted port reduces the need for multiple needle sticks. It is not yet known whether one type of port is more effective than another in reducing infections and other side effects associated with long-term port use.
PURPOSE: This randomized clinical trial is comparing two types of ports in patients with cancer receiving intravenous chemotherapy.
연구 개요
상세 설명
OBJECTIVES:
Primary
- To compare the rate of port failure, defined as the occurrence of port malfunction or port infection within 12 months after port insertion, in patients with cancer requiring long-term adjuvant intravenous chemotherapy undergoing insertion of a newly designed, FDA-approved Vortex® implantable vascular access port vs a conventional vascular access port.
Secondary
- To compare the rate of port malfunction or port infection at 6 and 12 months after port insertion.
- To compare the rate of central vein thrombosis at 6 and 12 months after port insertion.
- To compare the rate of port removal for any reason other than infection or occlusion at 6 and 12 months after port insertion.
- To compare the rate of termination of use of the indwelling port at 6 and 12 months after port insertion.
- To compare the death from all causes.
- To compare the incidence of port-related interventions at 6 and 12 months after port insertion.
OUTLINE: Patients are randomized to 1 of 2 intervention arms.
- Arm I: Patients undergo insertion of a conventional vascular access port. Patients then receive standard chemotherapy.
- Arm II : Patients undergo insertion of the Vortex® implantable vascular access port. Patients then receive standard chemotherapy.
All episodes of access to the port are documented for 12 months after port insertion. Information including the reason for port access and difficulty in access is collected. Complications, such as occlusion and infection, implant duration, and incidence of port-related interventions are assessed at 6 and 12 months after port insertion.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Florida
-
Jacksonville, Florida, 미국, 32224
- Mayo Clinic - Jacksonville
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Diagnosis of malignancy requiring intravenous chemotherapy for ≥ 6 months
- Must undergo entire course of chemotherapy at the Mayo Clinic in Jacksonville, unless the outside treating institution agrees to submit the research data sheet to Mayo Clinic
- Scheduled time frame for regular use of the vascular access port ≥ 3 months after port insertion
PATIENT CHARACTERISTICS:
- Life expectancy ≥ 6 months
No active skin condition implicating an elevated risk of local or systemic infectious or non-infectious complications, including any of the following:
- Current skin infection
- Cutaneous lymphoma
- Auto-immune disorders
- Active vasculitis
- Connective tissue diseases
No known active infection requiring antibiotic therapy at the time of port implantation
- Patients without an active infection who are on chronic antibiotic suppressive therapy are eligible
No concurrent illness requiring chronic anticoagulation
- Patients who develop other comorbidities requiring chronic anticoagulation during the study period are eligible
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Standard Port
Patients undergo insertion of the conventional vascular access port (C.
R. Bard, Inc., Murray Hill, NJ).
Patients then receive standard chemotherapy.
|
|
|
실험적: Vortex Implantable Access Port
Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA).
Patients then receive standard chemotherapy.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Port Failure Within 12 Months of Port Insertion
기간: Up to 12 months from port insertion
|
We report the proportion of patients in each treatment group who have some degree of port failure.
Port failure is defined as the composite outcome of port malfunction due to partial or total occlusion and any infection related to the port, within 12 months of port insertion.
The percentages reported here are the number of patients that had reported a port failure within 12 months out of the number of patients with port failure within 12 months plus the number of patients that were followed 12 months without port failure.
|
Up to 12 months from port insertion
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Death From All Causes
기간: Up to 12 months after port insertion
|
Number of patients that died during treatment due to any cause.
|
Up to 12 months after port insertion
|
|
Port Removal for Any Reason Other Than Infection or Occlusion Within 12 Months After Port Insertion
기간: Up to 12 months after port insertion
|
We report the number of patients that terminated use of port due to any reason other than infection or occlusion within 12 months.
|
Up to 12 months after port insertion
|
|
Termination of Use of the Indwelling Port at 12 Months After Port Insertion
기간: Up to 12 months after port insertion
|
The number of patients that discontinued use of inserted port for any reason at the 12 month timepoint.
|
Up to 12 months after port insertion
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- P30CA015083 (미국 NIH 보조금/계약)
- 52-04 (기타 식별자: Mayo Clinic Cancer Center & Mayo Clinic IRB)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .